Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival Background: Ipilimumab is a recently approved immunotherapy that has demonstrated an improvement in the overall survival (OS) of patients with metastatic melanoma. We report a single-institution experience in patients treated in a compassionate-use program.
introduction
Metastatic melanoma is a poor prognosis disease. This cancer has the steepest incidence rate worldwide and among skin cancers, it is the first cause of mortality with 20 100 deaths reported in 2008 in Europe [1] . The 5-year survival rate is 5%-10% and the median survival is 6-10 months [2, 3] . Until the recent development of new drugs such as immunotherapy and anti-BRAF-targeted agents, no therapy had been able to demonstrate any substantial overall survival (OS) benefit in patients with metastatic melanoma [4, 5] .
Ipilimumab (Yervoy®) is a monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 recently developed by Bristol-Myers Squibb. This fully human antibody (IgG1) downregulates a T-lymphocyte inhibitory pathway and potentiates the immune response against melanoma cells [6] . Ipilimumab improves OS in patients with pretreated metastatic melanoma [4] . In this phase III randomized trial, the median OS was 10.1 months in the ipilimumab group (at a dose of 3 mg/kg), versus 6.4 months in the group treated with a glycoprotein 100 peptide vaccine. Robert et al. [7] showed in another randomized phase III trial that ipilimumab at a dose of 10 mg/kg, in combination with dacarbazine, was associated with longer OS than dacarbazine alone (11.2 versus 9.2 months, respectively) in previously untreated patients with metastatic melanoma. These studies led to the approval of ipilimumab by the Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) as a second-line treatment of metastatic melanoma.
The issues encountered during clinical trials are noteworthy. First, the safety profile is unusual with new autoinflammatory side-effects called immune-related adverse events (irAEs) [8] . The cutaneous and gastrointestinal irAEs occur frequently, respectively, in 40% and 30% of patients, and can be life-threatening [9] . Hodi et al. [4] reported 12% of grade 3-4 severe colitis and 14 drug-related deaths (2.1%) in 643 patients receiving ipilimumab. The irAEs are dosedependent, usually manageable with high-dose corticosteroids and may, in severe and steroid-resistant cases, require more potent immunosuppressive drugs like anti-TNF-alpha [10, 11] . Secondly, the patterns of response to ipilimumab are different from those observed with cytotoxic agents. New evaluation criteria, which are more adapted to immunotherapeutic agents, have been developed to replace the Response Evaluation Criteria in Solid Tumors (RECIST, WHO Criteria). Indeed, ipilimumab and other immunotherapeutic agents, like anti-PD-1 antibodies, are now commonly evaluated using the so-called 'immune-related response criteria' [12] . Thus, an initial increase in the tumor burden and a delayed clinical response are new profiles physicians have learnt to recognize.
The main objective of this study was to evaluate ipilimumab's efficacy in terms of OS and safety in clinical practice. The secondary aim was to identify early biomarkers of activity among the routinely used biological parameters.
patients and methods
This monocentric prospective observational study systematically included patients receiving ipilimumab at the Gustave Roussy Institute, Villejuif, France, from June 2010 to September 2011, in the context of a compassionate-use program that preceded the official approval of the drug. The last data were collected in December 2011.
patients
Patients were eligible for inclusion if they (i) had a confirmed diagnosis of unresectable stage III to IV melanoma according to the 2009 AJCC melanoma staging and classification, (ii) had received at least one previous systemic therapy, (iii) were alive 12 weeks after the first ipilimumab perfusion and (iii) were receiving ipilimumab exclusively in the temporary authorization for use and not in parallel in a clinical trial. Other inclusion criteria were: at least 18 years of age and no specific therapy for melanoma during the previous 28 days. All histological types of melanoma, including mucosal and uveal melanoma, were eligible for inclusion. Exclusion criteria were the presence of an autoimmune disease, HIV, hepatitis B or C, pregnancy, concomitant malignancies, symptomatic brain metastases or concomitant systemic therapy for melanoma. Asymptomatic or pretreated brain metastases were not an exclusion criterion.
study design and treatment
Ipilimumab (Bristol-Myers Squibb) was administered intravenously over 90 min at a dose of 3 mg/kg of body weight every 3 weeks. Four infusions were required during the induction phase. In case of disease progression after an initial clinical benefit (defined as at least a partial response or stabilization of the disease for 3 months), patients were re-induced following the same protocol. Rapid disease progression or the occurrence of severe grade 3-4 toxicity led to treatment discontinuation.
Patients underwent a pretreatment evaluation including a physical examination, standard blood testing and a radiological evaluation of the disease.
During the induction phase, the clinical examination, adverse-event monitoring and laboratory tests (hemogram, liver, renal and thyroid function tests) were conducted before each ipilimumab infusion. Repeated CT scans of the brain, chest, abdomen and pelvis were carried out at 12 and 24 weeks after the first ipilimumab administration. In case of progressive disease at 12 weeks, an additional CT scan was carried out at 16 weeks. Blood tests were carried out every 3 weeks during induction and reinduction phases to identify biomarkers associated with increased survival.
safety
Adverse events were recorded from the time of the first ipilimumab administration until the end of the study. They were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse events, version 4.0. Adverse events occurring during ipilimumab therapy were thought to be immune-related if they were previously known as immune phenomenon in this context, and if other causes were ruled out [11, 13] . IrAE management was based on the guidelines approved by BMS and the FDA [14] .
end point
The evaluation of efficacy was based on survival and not on progressionfree survival nor the best objective tumor response. These latter parameters were not considered appropriate to appraise the real benefit of ipilimumab in this population, because survival was the major criterion reported in previous studies and RECIST were the evaluation criteria commonly used in our center at the time of the study [4, 7, 12] . Survival was defined as the time from baseline, defined as the date of ipilimumab initiation plus 12 weeks, to the time of death, to the last observation of the patient or to the date of the end of the observation period, 2.4 months after the last patient was included, whichever occurred first.
Characteristics such as the number of previous lines of chemotherapy, administration of corticosteroids, sex, LDH level, absolute lymphocyte count (ALC) and absolute eosinophil count (AEC) (normal range 0-400/ mm 3 ) were reported before ipilimumab therapy. Potential surrogate markers, such as the number of ipilimumab infusions, ALC and AEC, were collected during treatment. All these data were studied in univariate analysis.
statistical analysis
Categorical values at baseline were expressed as counts and percentages whereas continuous values were expressed as median and range values. Survival was defined as the time from inclusion to death due to any cause. OS was estimated by the Kaplan-Meier method. Median values and their confidence interval at 95% were given for each stratum. Cox proportional hazards models were used to identify covariates independently associated with survival. The variables with a P-value of <0.20 in the univariate analysis were evaluated in a multivariate Cox regression model with a backward stepwise strategy used to eliminate nonsignificant variables at P < 0.05. Descriptive statistics were used to analyze adverse events. Confidence intervals were at the 95% level. All analyses were carried out using the SAS® software (version 9.1, Cary, NC, USA).
results population
From June 2010 to September 2011, 96 patients were treated with at least one ipilimumab infusion in a compassionate-use program. Seventy-three patients were alive at 12 weeks and met selection criteria for inclusion in this study. These two populations were comparable for the values studied. Patient characteristics before ipilimumab therapy are reported in Table 1 . The mean age of patients was 58.5 years (range 19-86 years). Every patient had received prior systemic therapies, with a median number of one line of treatment (range 1-5).
Twenty-six patients (36%) had pretreated and/or asymptomatic brain metastases. All patients received at least one ipilimumab infusion. Fifty-three patients (73%) completed the induction phase and 6 of them (8%) were re-induced. The median number of doses received in the induction phase was three (range 2-4). Among the 20 patients (27%) who did not complete the induction phase, 11 experienced grade 3-4 adverse events and 9 rapidly developed progressive disease. One patient was lost to follow-up.
safety
Overall, 47 patients experienced adverse events (64%). The most common events were irAEs: 63 cases of irAEs were reported in 62% of the patients (45 out of 73), including 19 grade 3-4 events (26% of the patients). IrAEs are detailed in Table 2 . No treatment-related death occurred during the study. Gastrointestinal irAEs, such as diarrhea and colitis, were the most frequently observed adverse events. Ten cases of grade 3-4 colitis occurred, and were confirmed by colonoscopy and LDH, lactate deshydrogenase level; ULN, upper limit of normal.
Annals of Oncology original articles colonic biopsies. One case was complicated by an intestinal occlusion in a patient who also had small bowel metastases. All of these events resolved with corticosteroid therapy, except in two patients who required additional immunosuppression with anti-TNF-alpha (infliximab). Dermatological irAEs, detailed in Table 2 , were managed with symptomatic treatment and did not require interruption of the ipilimumab therapy. Two patients experienced liver enzyme elevation (grade 2 and 4). Both events were reversible within 2 weeks following corticosteroid therapy. Endocrine irAEs were rare and asymptomatic, mainly diagnosed on routine laboratory tests.
Non-irAEs included acute pulmonary edema, fever (two cases), renal failure secondary to pyelonephritis, hyponatremia, thrombocytopenia with bone marrow infiltration, cough, influenza-like symptoms, pneumonia and dyspnea.
efficacy and biomarkers associated with OS
The median OS was 9.1 months (95% CI 6.4-11.3) from the date of ipilimumab initiation (supplemental Figure S1 , available at Annals of Oncology online). The 1-year survival rate from ipilimumab initiation was 35.2% (95% CI 23.2-47.3). The number of prior systemic therapies (1 or ≥2), the administration of corticosteroid therapy, the lymphocyte and eosinophil counts at the first course were not associated with OS.
Patients were stratified by the number of courses of ipilimumab they received. Longer OS was observed in the group of patients with four or more ipilimumab courses: median OS was 10.7 months (95% CI 7.1-15.1), versus 6.3 months (95% CI 3.9-10.4) in the group of patients who had received <4 courses (log-rank test P = 0.026, Figure 1) . A normal LDH level before the first infusion was associated with better OS (P = 0.003) (Figure 2 ). Among the six re-induced patients, four died during the follow-up at 6, 7, 10 and 12 months, respectively, whereas two were alive at their last follow-up at 16 and 18 months. Median OS was 11.6 months in this group of patients.
Patients were stratified by their ALC before the second course of ipilimumab with a cut-off level of 1000/mm 3 . An ALC >1000/mm 3 at the time of the second course was associated with a substantial increase in OS. In this population, median OS was 11.1 months from the first ipilimumab infusion, versus 4.8 months when the ALC was <1000/mm 3 (log-rank test P < 0.0001, Figure 3A) . OS was also improved when the ALC differential was >200/mm 3 between the first and the second courses (P = 0.037, Figure 3B ). original articles
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Hypereosinophilia, defined as an AEC >400/mm 3 , was observed in 22 cases (30%). Seventy-seven percent of them had associated irAEs, involving mostly the gastrointestinal tract: seven patients experienced diarrhea and four had colitis. Cutaneous adverse events were reported in four cases. One case of hepatitis and one case of hypothyroidism were associated with hypereosinophilia. Five patients had hypereosinophilia with no other side-effects.
An increase >100/mm 3 in the AEC was associated with longer survival (median OS of 11.3 months versus 6.8 months, P = 0.012, Figure 4A ) as well as an increase >100% in the AEC between the first two ipilimumab courses (P = 0.062, Figure 4B ).
In the multivariate analysis, the number of ipilimumab courses and the ALC at the start of the second course were independently associated with OS: patients with fewer than four courses of ipilimumab were at higher risk of death than patients with four or more courses of ipilimumab (hazard ratio 2.0; 95% CI 1.1-3.9), and patients with an ALC <1000/mm 3 at the start of the second course were at higher risk of death than patients with an ALC >1000/mm 3 (hazard ratio 3.7; 95% CI 2.0-6.8).
All irAEs occurring during the first 12 weeks following the first infusion were defined as early toxic effect and were not correlated with OS (data not shown).
discussion
We present here the largest study describing the effects of ipilimumab in a real-life setting and the only one using this drug at the recommended dose of 3 mg/kg. The weakness of our study, as in every observational study, is the difficulty of controlling for potential selection bias. Our goal was to evaluate the effect of ipilimumab in a more homogeneous population of patients to conduct analyses in patients who may benefit from ipilimumab therapy. To this end, we excluded from our study the patients who died during the three first months of ipilimumab therapy. This concerned 23 patients who had very We report a median OS of 9.1 months from the start of the ipilimumab therapy which is in line with the results of the previous phase III trial, which reported an OS of 10 months [4] . Therefore, in this study, only patients with a performance status ≤1 were included, and deaths occurring during the first 12 weeks of ipilimumab therapy were not excluded.
The irAEs documented were consistent with the results of previous studies involving ipilimumab at the dose of 3 mg/kg [9] . In contrast with earlier studies, the occurrence of adverse events, particularly immune-related ones, was not correlated with OS [15] . IrAEs were manageable and reversible in the majority of cases following the early use of corticosteroids as indicated in the management algorithms that are now recommended [14] . Following these guidelines probably prevented the occurrence of severe adverse events such as bowel perforation, peritonitis or drug-related deaths that occurred in the initial trials, when investigators failed to appropriately manage ipilimumab toxicity [4, 16] . Furthermore, the use of the drug at a dose of 3 mg/kg may have a better safety profile than a dose of 10 mg/kg [10, 17] . However, the occurrence of new adverse events was observed in two patients: one with neutrophilic dermatosis and another with acquired hemophilia (that we previously reported [18] ), indicating that the spectrum of adverse events that might be observed with ipilimumab may still be extended, and that physicians need to continue to closely monitor their patients for potential new irAEs.
To adjust the results in the multivariate analysis, patients were stratified according to known prognostic factors such as the LDH level at baseline [2, 19] . In the univariate analysis, the number of ipilimumab courses appeared to be an adjustment variable. Survival improvement in patients who received more than four ipilimumab courses remained important after adjustment on confounding factors, which could be interpreted as a marker of treatment efficacy or slower disease progression.
The increase in the ALC that occurred 3 weeks after the first ipilimumab course at a dose of 3 mg/kg was substantially associated with improved OS in uni-and multivariate analyses. This was consistent with results reported in previous smaller scale studies in which ipilimumab was administered at a dose of 10 mg/kg in compassionate-use settings [20, 21] . There was also a non-significant trend towards an improved OS for patients with an ALC >1000/mm 3 before treatment, which may be considered as a pre-treatment predictive factor for response (supplemental Figure S2 , available at Annals of Oncology online).
To the best of our knowledge, we report the first association between the AEC and improved OS in patients treated with ipilimumab. The eosinophil count could be increased secondarily due to an immuno-allergic process or to lymphocytosis. Since CD28/B7 interaction seems to play a crucial role in the induction of allergic inflammation, i.e. eosinophil increase, IL-5 production and IgE production, it is conceivable that blocking CTLA4 immune checkpoint could lead to exacerbated allergic manifestations [22] . In mice, in an airway inflammation model, blockade of CTLA4 has been described to promote allergic eosinophilic inflammation as well as to increase IL-5 production and antigen-specific IgE secretion [23] .
The use of these two biomarkers as early markers of response needs to be explored in further studies. Indeed, the relatively low percentage of response to ipilimumab therapy and its substantial toxic effect encourage us to search for more predictive and 'easy-to-use' biomarkers that could lead to the early identification of patients likely to respond to ipilimumab therapy, and to avoid its undesirable side-effects in other patients who are unlikely to respond.
To conclude, ipilimumab at 3 mg/kg is a practicable treatment in daily practice for advanced metastatic melanoma patients. Clinical response can be obtained in heavily pretreated patients with disease progression. IrAEs identified in phase II and III trials of ipilimumab occurred in this population and were generally reversible following the early use of corticosteroid therapy. Absolute lymphocyte and eosinophil counts appear to be early biomarkers of ipilimumab efficacy. 
